Table 2.

Gene expression probe sets associated with outcome (EFS) in the entire infant ALL cohort

Rank	Probe set	Gene symbol	Elevated in*	SAM analysis		Cox regression analysis		P (adjusted for MLL)†	P (adjusted for age)‡
				Score	FDR (%)	HR	P§
1	211382_s_at	TACC2	High risk	2.50	< 1	1.51	.001	.007	.001
2	228462_at	IRX2	High risk	2.23	< 1	1.45	.001	.006	.002
3	202289_s_at	TACC2	High risk	2.15	< 1	1.42	.003	.028	.007
4	205403_at	IL1R2	High risk	1.99	< 1	1.48	.001	.018	.016
5	206674_at	FLT3	High risk	1.94	< 1	1.54	.009	.248	.002
6	202609_at	EPS8	High risk	1.78	9.77	1.38	.004	.030	.009
7	220448_at	KCNK12	High risk	1.77	9.77	1.39	.019	.428	.015
8	204150_at	STAB1	High risk	1.77	9.77	1.42	.003	.019	.012
9	214156_at	MYRIP	High risk	1.76	9.77	1.49	.001	.008	.008
10	204069_at	MEIS1	High risk	1.72	9.77	1.37	.027	.650	.016

Bold denotes probe sets that are used for building the regression tree model.

^*Indicates risk group with which elevated expression is correlated.

^†P value indicating significance of the association between the expression of each gene and treatment outcome adjusting for the MLL status.

^‡P value indicating significance of the association between the expression of each gene and treatment outcome adjusting for age effect.

^§P value of Wald test for the HR indicating significance of the association between the expression of each individual gene and treatment outcome.